View Older Stories

May 15, 2026 04:30PM Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update

May 5, 2026 08:00PM Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization

Apr 29, 2026 08:00AM Citius Oncology Ships First International Order of LYMPHIR™ to Europe

Apr 24, 2026 04:30PM Citius Pharmaceuticals closes $5 million registered direct offering

Apr 24, 2026 04:30PM Citius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules

Apr 24, 2026 08:00AM Citius Pharmaceuticals raises $5 million in registered direct offering

Apr 24, 2026 08:00AM Citius Pharmaceuticals Announces a Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules

Mar 31, 2026 09:13AM Citius Oncology reports early commercial progress for LYMPHIR drug launch

Mar 31, 2026 09:11AM Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development

Mar 24, 2026 08:00AM Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts

Mar 10, 2026 08:47AM Citius Oncology reports phase 1 trial results for gynecologic cancers

Mar 10, 2026 08:47AM Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers

Mar 4, 2026 09:15AM Citius Oncology reports positive phase 1 data for LYMPHIR cancer treatment

Mar 4, 2026 09:15AM Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma

Feb 24, 2026 08:00AM Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program

Feb 13, 2026 08:00AM Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™

Feb 13, 2026 08:00AM Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™

Feb 11, 2026 08:02AM Citius Oncology signs exclusive European distribution deal with Uniphar

Feb 11, 2026 08:00AM Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar

Dec 23, 2025 04:31PM Citius Pharmaceuticals launches cancer drug LYMPHIR following FDA approval

Dec 23, 2025 04:30PM Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

Dec 23, 2025 04:30PM Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

Dec 10, 2025 04:30PM Citius Oncology closes $18 million stock offering at $1.09 per share

Dec 10, 2025 04:30PM Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules

Dec 9, 2025 08:30AM Citius Oncology raises $18 million in stock offering for LYMPHIR launch

Dec 9, 2025 08:30AM Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules

Dec 4, 2025 08:37AM Citius Oncology partners with Er-Kim for LYMPHIR distribution in Turkey, GCC

Dec 4, 2025 08:37AM Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim

Dec 1, 2025 12:08PM Citius Oncology launches LYMPHIR cancer treatment nationwide

Dec 1, 2025 12:00PM Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)

Nov 25, 2025 08:00AM Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting

Nov 21, 2025 08:37AM Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration

Oct 21, 2025 04:30PM Citius Pharmaceuticals closes $6 million direct offering

Oct 21, 2025 04:30PM Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules

Oct 21, 2025 08:01AM Citius Pharmaceuticals raises $6 million in registered direct offering

Oct 21, 2025 08:00AM Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules

Oct 20, 2025 08:38AM Citius Oncology signs distribution deal with McKesson for LYMPHIR launch

Oct 20, 2025 08:37AM Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch

Oct 17, 2025 05:00PM Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences

Oct 16, 2025 08:47AM Citius Oncology partners with EVERSANA for LYMPHIR drug launch

Oct 16, 2025 08:47AM Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™

Oct 7, 2025 08:47AM Citius Oncology Establishes International Access to LYMPHIR™ via Named Patient Programs in Southern Europe

Sep 10, 2025 04:30PM Citius Oncology closes $9 million equity offering

Sep 10, 2025 04:30PM Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

Sep 9, 2025 08:30AM Citius Oncology prices $9 million offering at $1.75 per share

Sep 9, 2025 08:30AM Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

Aug 22, 2025 08:47AM Citius Oncology deploys AI platform ahead of LYMPHIR launch

Aug 22, 2025 08:47AM Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch

Aug 12, 2025 04:30PM Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update

Aug 12, 2025 04:30PM Citius Oncology, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update

View Older Stories